caa a22 4500 46911987X CHVBK 20180323133135.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF02245310 doi (NATIONALLICENCE)springer-10.1007/BF02245310 Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers [Elektronische Daten] [F. Kamali, S. Stansfield, C. Ashton, G. Hammond, M. Emanuel, M. Rawlins] The possible development of withdrawal symptoms following abrupt discontinuation of ritanserin after chronic administration of 10 mg daily for 8 weeks was investigated in a placebo controlled trial in 40 healthy subjects. The study consisted of two phases. In the first phase, under single blind conditions, all subjects received placebo for 2 weeks followed by a single daily dose of ritanserin (10 mg) for 8 weeks. In the second phase, under double blind conditions, subjects were randomised to receive either placebo or to continue on ritanserin (10 mg) for a further 4 weeks. Psychological assessments were performed at the start of and at intervals throughout the study. Levels of anxiety, concentration, quality of sleep and morning vigilance were measured throughout by daily visual analogue scales. No significant changes were detected in any of the measures in the group of subjects who received ritanserin compared to the group who received placebo during the second phase of the study. Ritanserin discontinuation following chronic dosing in healthy volunteers does not appear to be associated with withdrawal symptoms. Springer-Verlag, 1992 Ritanserin nationallicence Anxiety nationallicence Sleep nationallicence Withdrawal effects nationallicence Kamali F. Department of Pharmacological Sciences, University of Newcastle upon Tyne, NE1 7RU, Tyne, UK aut Stansfield S. Janssen Research Foundation, Janssen Pharmaceutical Ltd, Grove, Wantage, UK aut Ashton C. Department of Pharmacological Sciences, University of Newcastle upon Tyne, NE1 7RU, Tyne, UK aut Hammond G. Janssen Research Foundation, Janssen Pharmaceutical Ltd, Grove, Wantage, UK aut Emanuel M. Janssen Research Foundation, Janssen Pharmaceutical Ltd, Grove, Wantage, UK aut Rawlins M. Department of Pharmacological Sciences, University of Newcastle upon Tyne, NE1 7RU, Tyne, UK aut Psychopharmacology Springer-Verlag 108/1-2(1992-07-01), 213-217 0033-3158 108:1-2<213 1992 108 213 https://doi.org/10.1007/BF02245310 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245310 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kamali F. Department of Pharmacological Sciences, University of Newcastle upon Tyne, NE1 7RU, Tyne, UK aut NATIONALLICENCE 700 1- Stansfield S. Janssen Research Foundation, Janssen Pharmaceutical Ltd, Grove, Wantage, UK aut NATIONALLICENCE 700 1- Ashton C. Department of Pharmacological Sciences, University of Newcastle upon Tyne, NE1 7RU, Tyne, UK aut NATIONALLICENCE 700 1- Hammond G. Janssen Research Foundation, Janssen Pharmaceutical Ltd, Grove, Wantage, UK aut NATIONALLICENCE 700 1- Emanuel M. Janssen Research Foundation, Janssen Pharmaceutical Ltd, Grove, Wantage, UK aut NATIONALLICENCE 700 1- Rawlins M. Department of Pharmacological Sciences, University of Newcastle upon Tyne, NE1 7RU, Tyne, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 108/1-2(1992-07-01), 213-217 0033-3158 108:1-2<213 1992 108 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer